A retrospective analysis was conducted to determine the effects of metformin on glycosylated hemoglobin (HbA1c), body weight, and adverse events in an African-American population.
Thirty-six patients who were receiving combination therapy with metformin and either a sulfonylurea or insulin were identified from a hospital pharmacy database.
Nineteen patients met the criteria for efficacy analysis.
The combination of metformin with either a sulfonylurea or insulin resulted in a decrease of the average HbA1c from a baseline of 10.07% to 7.92% (delta=2.15%). The effect of combination therapy on weight was variable ; however, twice as many patients lost weight compared with those who gained weight.
Metformin appeared to be well-tolerated, with gastrointestinal symptoms being the most commonly reported adverse events.
Mots-clés Pascal : Diabète non insulinodépendant, Poids corporel, Rétrospective, Metformine, Pharmacocinétique, Facteur efficacité, Hémoglobine A1, Africain, Américain, Etude comparative, Homme, Biguanides, Endocrinopathie, Hypoglycémiant, Activité biologique
Mots-clés Pascal anglais : Non insulin dependent diabetes, Body weight, Retrospective, Metformin, Pharmacokinetics, Effectiveness factor, Hemoglobin A1, African, American, Comparative study, Human, Biguanides, Endocrinopathy, Hypoglycemic agent, Biological activity
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0016118
Code Inist : 002B02N. Création : 17/04/1998.